In this study, we used the third-generation EGFR-TKI Almonertinib in combination with SLC1A5 inhibitor to investigate the changes in the sensitivity of NSCLC cells to Almonertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.